The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Official Title: Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
Study ID: NCT02862613
Brief Summary: Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.
Detailed Description: A total of 40 patients may be enrolled over a period of 1-2 years.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Shanghai International Medical Center, Shanghai, Shanghai, China
Name: Naiyan Han
Affiliation: Shanghai International Medical Center
Role: STUDY_CHAIR